The third time is not the charm for Hengrui Pharma and Elevar Therapeutics. The pair’s star-crossed cancer drug combination of camrelizumab and rivoceranib has been rejected by the FDA for the third time.
Source: FiercePharma
You may also like
This common pesticide may be quietly wiping out future...
Boehringer Ingelheim’s Jascayd approved by MHRA for...
Ipsen to acquire Memo Therapeutics in deal worth more...
Macrophage Membrane-Derived Nanoparticles Shows...
Epigenomic Analysis Uncovers New AML Subgroups and...
GSK, Hansoh ADC extends survival in lung cancer study
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.